0001607062-17-000038.txt : 20170127 0001607062-17-000038.hdr.sgml : 20170127 20170127100238 ACCESSION NUMBER: 0001607062-17-000038 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170127 DATE AS OF CHANGE: 20170127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regen BioPharma Inc CENTRAL INDEX KEY: 0001589150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455192997 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-191725 FILM NUMBER: 17551961 BUSINESS ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 BUSINESS PHONE: 619-702-1404 MAIL ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 10-Q 1 rgbp123116form10q.htm FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada		45-5192997
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 702 1404

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☐ Non-accelerated filer	☒ Smaller reporting company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of December 31, 2016 there were 145,412,605 shares of common stock issued and outstanding.

As of December 31, 2016 there were 147,966,697 shares of Series A Preferred Stock issued and outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

REGEN BIOPHARMA , INC.
BALANCE SHEET

	As of			As of
	December 31, 2016			September 30, 2016
	(unaudited)
CURRENT ASSETS
Cash		220,718			24,822
Accounts Recievable		83,000			83,000
Note Recievable		12,051			12,051
Prepaid Expenses		61,011			69,905
Accrued Interest Recievable		2,878			2,578
Due from Former Employees		15,000			15,000
Total Current Assets		394,658			207,356

OTHER ASSETS
Available for Sale Securities		312,000			112,000
Total Other Assets		312,000			112,000

TOTAL ASSETS		706,658			319,356

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Bank Overdraft		0			0
Accounts payable		163,927			240,759
Notes Payable		68,638			143,447
Accrued payroll taxes		3,677			33,040
Accrued Interest		54,841			43,918
Accrued Reent		20,000			15,000
Accrued Payroll		349,496			263,996
Due to Shareholder		25,000			50,000
Convertible Notes Payable		47,425			9,041
Total Current Liabilities		733,004			799,201
Long Term Liabilities:
Convertible Notes Payable		129,776			107,057
Total Long Term Liabilities		129,776			107,057
Total Liabilities		862,779			906,258

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 145412605 issued and outstanding as of December 31, 2016 and 139,712,605 shares issuedand outstanding September 30, 2016		14,540			13,970
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of September 30, 2016 and December 31, 2016 respectively
Series A Preferred 300,000,000 authorized, 147966697 and 135,266,697 outstanding as of December 31, 2016 and September 30, 2016 respectively		14,797			13,527
Series AA Preferred $0.0001 par value 600,000 authorized and 30, 000 outstanding as of December 31, 2016 and September 30, 2016		3			3
Additional Paid in capital		21,714,779			18,961,259
Contributed Capital		728,658			728,658
Retained Earnings (Deficit) accumulated during the development stage		(22,748,898	)		(20,224,319	)
Accumulated Other Comprehensive Income		120,000			(80,000	)
Total Stockholders' Equity (Deficit)		(156,121	)		(586,902	)

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)		706,658			319,356

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
STATEMENT OF OPERATIONS
(unaudited)

	Quarter Ended		Quarter Ended
	December 31, 2016		December 31, 2015
REVENUES	0		0

COST AND EXPENSES
Research and Development	42,694		105,323
General and Administrative	242,758		488,596
Consulting and Professional Fees	233,128		80,533
Rent	15,000		15,000
Total Costs and Expenses	533,580		689,452

OPERATING LOSS	(533,580	)	(689,452	)

OTHER INCOME & (EXPENSES)
Interest Income	300		300
Other Income	31,846
Refunds of amounts previously paid
Interest Expense	(11,923	)	(5,001	)
Interest Expense attributable to Amortization of Discount	(61,102	)
Loss on issuance of common shares for less than fair value	(1,950,120	)	(1,163,313	)
Preferred shares issued pursuant to contractual obligations
TOTAL OTHER INCOME (EXPENSE)	(1,990,999	)	(1,168,014	)

NET INCOME (LOSS)	(2,524,579	)	(1,857,466	)
BASIC AND FULLY DILUTED
EARNINGS (LOSS) PER SHARE	(0.018	)	(0.0157	)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING	143,596,121		118,216,582

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.
STATEMENT OF COMPREHENSIVE INCOME
(unaudited)
	Quarter Ended December 31
	2016			2015
Net Income (Loss)	$	(2,524,579	)	$	(1,857,466	)
Add:
Unrealized Gains on Securities		200,000
Less:
Unrealized Losses on Securities					(38,400	)
Total Other Comprehensive Income (Loss)		200,000			(38,400	)
Comprehensive Income	$	(2,324,579	)		(1,895,866	)

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA , INC.
STATEMENT OF CASH FLOWS
(unaudited)

	Quarter Ended December 31			Quarter Ended December 31
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES

Net Income (loss)		(2,524,579	)		(1,857,466	)
Adjustments to reconcile net Income to net cash
Stock Received as Payment for Services
Preferred Stock Issued for Expenses
Preferred Stock issued for compensation
Preferred Stock issued for Interest
Preferred Stock issued pursuant to contractual obligations
Common Stock issued to Consultants
Preferred Stock issued to Consultants					40
Increase (Decrease) in Interest expense attributable to amortization of Discount		61,102
Increase in issuance of stock below fair value		1,950,120			1,163,313
Increase in Additional Paid in Capital		5,240			247,723
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Payable		(76,832	)		1,792
(Increase) Decrease in Accounts Receivable
(Increase) Decrease in Notes Receivable
(Increase) Decrease in Interest Receivable		(300	)		(300	)
Increase ( Decrease) in Bank Overdraft
Increase (Decrease) in accrued Expenses		72,060			25,495
(Increase) Decrease in Prepaid Expenses		8,894			9,000
(Increase) Decrease in Due from Former Employee					(15,000	)

Net Cash Provided by (Used in) Operating Activities		(504,295	)		(425,403	)

CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash		267,500			32,1667
Preferred Stock issued for Cash		292,500			238,334
Increase in Contributed Capital		0
Increase ( Decrease) in Notes Payable		(74,809	)		(54,701	)
Increase in Convertible Notes payable		240,000
Increase (Decrease) in Due to Shareholder		(25,000	)		50,000
Net Cash Provided by (Used in) Financing Activities		700,191			555,300


Net Increase (Decrease) in Cash		195,896			129,897

Cash at Beginning of Period		24,822			38,620

Cash at End of Period		220,718			168,517

Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt		0
Preferred Shares Issued for Debt		0
Cash Paid for Interest		1,000

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.

Notes to Financial Statements

As of December 31, 2016

The accompanying unaudited interim condensed consolidated financial statements of Regen Biopharma , Inc. (“Regen” or “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the United States Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report filed with the SEC on Form 10-K for the year ended September 30, 2016. In general, interim disclosures do not repeat those contained in the annual statements. In the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a controlled subsidiary of Bio-Matrix Scientific Group, Inc, (“BMSN”) a Delaware corporation.

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

E. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .

I. REVENUE RECOGNITION

Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products.

The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared

under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 22,748,898 during the period from April 24, 2012 (inception) through December 31, 2016. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the year ended September 30, 2016 the Company raised $1,254,751 through the issuance of equity securities for cash and $300,000 through the issuance of convertible debentures. During the quarter ended December 31, 2016 the Company raised $585,000 through the issuance of equity securities for cash and $240,000 through the issuance of convertible debentures.

NOTE 4. NOTES PAYABLE

	December 31, 2016
David Koos ( Note 8)		50
Bostonia Partners		68,588
Notes payable	$	68,638

$50 lent to the Company by David Koos. is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$5,288 lent to the Company by Bostonia Partners is due and payable March 8, 2017 and bears simple interest at a rate of 10% per annum.

$63,300 lent to the Company by Bostonia Partners is due and payable May 10 2017 and bears simple interest at a rate of 10% per annum.

NOTE 5. CONVERTIBLE NOTES PAYABLE

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities.

The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible notes outstanding is $ 31,085. As of December 31, 2016 $100,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is $0.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 7,495. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

On August 26, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 32,739. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On September 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 34,657. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On September 20, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 36,164. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On October 7, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 44,178. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On October 31, 2016 (“Issue date”) the Company issued a second Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 45,821. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On October 31, 2016 (“Issue date”) the Company issued a third Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 45,821. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On October 31, 2016 (“Issue date”) the Company issued a fourth Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 45,821. As of December 31, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$278,000 if the entire principal amount is converted into common stock

(b)

$209,600 if the entire principal amount is converted into Series A Preferred stock

On December 22, 2016 (“Issue date”) the Company issued a fifth Convertible Note (“Note”) in the face amount of $40,000 for consideration consisting of $40,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.01 per share.

The issuance of the Note amounted in a beneficial conversion feature of $40,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2016 the unamortized discount on the convertible note outstanding is $ 39,013. As of December 31, 2016 $40,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of December 31, 2016 is :

(a)

$288,000 if the entire principal amount is converted into common stock

(b)

$219,600 if the entire principal amount is converted into Series A Preferred stock

NOTE 6. NOTES RECEIVABLE

	December 31, 2016
Entest Biomedical, Inc. (Note 8)	$	12,051

Notes Receivable	$	12,051

$12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

NOTE 7. INCOME TAXES

As of December 31, 2016

Deferred tax assets:
Net operating tax carry forwards	$	7,734,625
Other		-0-
Gross deferred tax assets		7,734,625
Valuation allowance		(7,734,625)
Net deferred tax assets	$	-0-

As of December 31, 2016 the Company has a Deferred Tax Asset of $7,734,625 completely attributable to net operating loss carry forwards of approximately $22,748,898 (which expire 20 years from the date the loss was incurred).

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to 0.

Income tax is calculated at the 34% Federal Corporate Rate.

NOTE 8. RELATED PARTY TRANSACTIONS

As of December 31, 2016 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.

The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.

As of December 31, 2016 Entest Biomedical Inc. is indebted to the Company in the amount of $12,051. $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

As of December 31, 2016 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a wholly owned subsidiary of Entest Biomedical, Inc.

Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15^th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance.

Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by The Company:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On September 28, 2015 Zander caused to be issued to the Company 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to the Company by Zander as a license initiation fee. Regen Biopharma, Inc. recognized revenue of $192,000 equivalent to the fair value of 8,000,000 of the common shares of Entest Biomedical, Inc as of the date of issuance.

During the quarter ended September 30, 2016 Zander paid $17,000 to the Company as a partial payment of the July 15^th, 2016 liability

David R. Koos serves as sole officer and director of both Zander and Entest Biomedical, Inc. and also serves as Chairman and Chief Executive Officer of The Company.

NOTE 9. COMMITMENTS AND CONTINGENCIES

NOTE 10. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31, 2016:

Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 145,412,605 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of December 31, 2016 and 300,000,000 is designated Series A Preferred Stock of which 147,966,697 shares are outstanding as of December 31, 2016.

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

Series AA Preferred Stock

On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).

The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Series A Preferred Stock

On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”).

The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

11. INVESTMENT SECURITIES

On September 28, 2015 Zander Theraputics, Inc. caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander Theraputics, Inc as a license initiation fee.

The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities as of December 31, 2016.

As of December 31, 2016:

	8,000,000		Common Shares of Entest Biomedical, Inc.

	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2016
$	192,000	$	$312,000	120,000	200,000

NOTE 12. STOCK TRANSACTIONS

Common Stock

On November 8, 2016 the Company sold 5,000,000 of its Common Shares for consideration of $112,500.

On November 9, 2016 the Company sold 500,000 of its Common Shares for consideration of $12,500.

On December 19, 2016 the Company sold 7,700,000 of its Common Shares for consideration of $142,500

Series A Preferred Stock

On November 8, 2016 the Company sold 5,000,000 of its Series A Preferred Shares for consideration of $112,500.

On November 9, 2016 the Company sold 500,000 of its Series A Preferred Shares for consideration of $12,5000

On December 19, 2016 the Company sold 9,700,000 of its Series A Preferred Shares for consideration of $ 167,500

Cancellation of Officer Shares

On December 27, 2016 Todd Caven, the Company’s Chief Financial Officers, agreed to the cancellation of 7,500,000 of his personally owned Common Shares of the Company. No consideration was paid to Mr. Caven for this cancellation.

On December 30, 2016 Todd Caven, the Company’s Chief Financial Officers, agreed to the cancellation of 2,500,000 of his personally owned Series A Preferred Shares of the Company. No consideration was paid to Mr. Caven for this cancellation.

NOTE 13. CHANGES AFFECTING COMPARIBILITY

Within the Company’s Statement of Cash Flows for the Quarters Ended December 31, 2015 and 2016 the line item entitled “Increase (Decrease) in Additional paid in Capital” which represents Restricted Stock Award compensation expense recognized for the periods on Restricted Stock Awards issued to employees is presented as an adjustment to reconcile net loss to net cash used in operating activities. The Company’s previously released Statement of Cash Flows for the Quarter Ended December 31, 2015 presented the same line item as a financing activity. Management has determined that such presentation does not best reflect the nature of the expense incurred and has adjusted the prior period accordingly.

NOTE 14. SUBSEQUENT EVENTS

On January 5, 2017 the Company sold 1,000,000 of its Common Shares for consideration of $12,500

On January 5, 2017 the Company sold 1,000,000 of its Series A Preferred Shares for consideration of $ 12,500

On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock").

The Board of Directors of Regen have authorized 300,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

Material Changes in Financial Condition

As of December 31, 2016, we had Cash of $ 220,718 and as of September 30, 2016 we had Cash of $24,822.

The increase in cash of approximately 789.21% is primarily attributable to:

(a)

$560,000 of equity securities sold for cash

(b)

$240,000 of convertible notes sold for cash

(c)

$25,000 deposited by an unaffiliated investor pursuant to an agreement whereby the unaffiliated investor agreed to buy and the Company agreed to sell equity securities of the Company. As of December 31, 2016 the securities issuable pursuant to the agreement had yet to be issued to the unaffiliated investor.

Offset by:

(a)

Net reduction of Notes Payable of $74, 809

(b)

Costs of conducting the business of the Company

As of September 30, 2016 we had Prepaid Expenses of $ 69,905 and as of December 31, 2016 we had Prepaid Expenses of $61,011.

The decrease in Prepaid Expenses of approximately 12.7% attributable to the recognition during the quarter ended December 31, 2016 of $8,894 of expenses which had been prepaid by the company during the quarter ended September 30, 2016

As of September 30 , 2016 we had Accrued Interest Receivable of $ 2,578 and as of December 31, 2016 we had Accrued Interest Receivable of $2,878

The increase in of Accrued Interest Receivable of approximately 11.6% is attributable to interest accrued but unpaid during the three months ended December 31 , 2016 resulting from amounts due to the Company by Entest Bio-Medical, Inc. David R. Koos serves as Chairman of the Board and Chief Executive Officer of both the Company and Entest Bio-Medical, Inc.

As of September 30, 2016 we had Available for Sale Securities of $112,000 and as of December 31, 2016 we had Available for Sale Securities of $312,000

The increase in Available for Sale Securities of 178 % is attributable to unrealized gains recognized on 8,000,000 common shares of Entest Biomedical, Inc. owned by the Company.

As of September 30, 2016 we had Accounts Payable of $240,759 and as of December 31, 2016 we had Accounts payable of $163,927.

The decrease in Accounts Payable of approximately 31.9% is attributable to decreases in outstanding obligations of the Company incurred in the course of business.

As of September 30,2016 we had Notes Payable of $143,447 and as of December 31, 2016 we had Notes Payable of $ 68,638 .

The decrease in Notes Payable of approximately 52.1% is attributable to the repayment of $74,809 of principal indebtedness during the three months ended December 31, 2016.

As of September 30, 2016 we had Accrued Payroll Taxes of $33,040 and as of December 31, 2016 we had Accrued Payroll Taxes of $3,677.

The decrease in Accrued Payroll Taxes of approximately 89% is attributable to the derecognition of $31, 846 of employer payroll tax payable resulting from the cancellation within the same calendar year of vesting of :

(a)

7,500,000 shares of Regen’s common stock personally owned by Todd S. Caven, Regen’s Chief Financial Officer, issued as compensation

(b)

2,500,000 shares of Regen’s Series A Preferred personally owned by Todd S. Caven issued as compensation.

As of September 30, 2016, we had Accrued Payroll of $263,996 and as of December 31, 2016 we had Accrued Payroll of $349,496.

The increase in Accrued Payroll of approximately 32.3% is attributable to :

(a)

$45,000 in salary expense due to the Company’s Chief Executive Officer incurred but unpaid during the three months ended December 31, 2016

(b)

$40,500 in salary expense due to the Company’s Chief Financial Officer incurred but unpaid during the three months ended December 31, 2016

As of September 30, 2016 we had Accrued Interest of $43,918 and as of December 31, 2016 we had Accrued Interest of $54,841.

The increase in Accrued Interest of approximately 24.9% is attributable to interest expense on Notes Payable and Convertible Notes Payable incurred during the three months ended December 31, 2016 but not yet paid.

As of September 30,2016 we had Convertible Notes Payable of $300,000 and as of December 31, 2016 we had Convertible Notes Payable of $ 540,000.

The increase in Convertible Notes Payable of 80% is attributable to Convertible Notes with an aggregate face value of $240,000 having been sold for $240,000 cash by the Company during the quarter ended December 31, 2016.

As of September 30, 2016 we had Amounts due to Shareholder of $50,000 and as of December 31, 2016 we had Amounts Due to Shareholder of $25,000.

The decrease in Amount due to Shareholder of 50% is attributable to the following:

On July 13, 2016 the Company entered into an agreement (“Agreement”) with an outside investor whereby the investor agreed to buy and the Company agreed to sell 1,000,000 Units for consideration of $50,000. Each Unit issuable pursuant to the Agreement shall consist of one share of the Company’s common stock and three shares of the Company’s Series A Preferred Stock. During the quarter ended September 30, 2016 the outside investor paid consideration to the Company of $50,000 for One Million Units. As of September 30, 2016 the securities issuable pursuant to the Agreement have not been issued. During the quarter ended December 31, 2016 the securities issuable pursuant to the Agreement were issued reducing Amount due to Shareholder by $50,000.

On December 22, 2016 the Company entered into an agreement (“Agreement”) with an outside investor whereby the investor agreed to buy and the Company agreed to sell 1,000,000 Units for consideration of $25,000. Each Unit issuable pursuant to the Agreement shall consist of one share of the Company’s common stock and one share of the Company’s Series A Preferred Stock. During the quarter ended December 31, 2016 the outside investor paid consideration to the Company of $25,000 for One Million Units. As of December 31, 2016 the securities issuable pursuant to the Agreement have not been issued.

As of September 30, 2016 we had Accrued Rent of $15,000 and as of December 31, 2016 we had Accrued Rent of $20,000.

The increase in Accrued Rent of 33.23% is attributable to Rental Expenses accrued but unpaid for the months of September 2016, October 2016, November 2016 and December 2016.

Material Changes in Results of Operations

Revenues from operations were $0 for the three months ended December 31, 2016 and -0- for the three months ended December 31, 2015. Net Losses were $2,524,579 for the three months ended December 31, 2016 and $ 1,857,466 for the same period ended 2015.

The increase in Net Losses of approximately 35.9% is primarily attributable to increases in expenses recognized resulting from the issuance for less than fair value of equity securities during the quarter ended December 31, 2016 as compared to the same period ended 2015, increases in consulting expenses recognized during the quarter ended December 31 2016 as compared to the same period ended 2015, increases in interest expense as well as interest expense attributable to amortization of discount attributable to Beneficial Conversion Features recognized on Convertible Notes recognized during the quarter ended December 31 2016 as compared to the same period ended 2015 offset by decreases in Research and Development as well as General and Administrative expenses recognized during the quarter ended December 31 2016 as compared to the same period ended 2015 as well as the recognition during the quarter ended December 31 2016 of Other Income of $31,846 recognized in connection with elimination of certain payroll tax liabilities ..

As of December 31, 2016 we had $220,718 cash on hand and current liabilities of $733,004 such liabilities consisting of Accounts Payable, Notes Payable, Amounts Due to Shareholder and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

The Company plans to meet cash needs through applying for governmental and non-governmental grants as well as selling its securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. Management can give no assurance that any governmental or non-governmental grant will be obtained by the Company despite the Company’s best efforts. As of February 19, 2014 The Company has identified the National Heart Lung and Blood Institute Clinical Trial Pilot Studies (R34) grant which provides up to $450,000 in funding over a period of three years as well as the Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications administered by the Small Business Innovation Research (SBIR) program of the National Institute of Health as grants for which the Company intends to apply.

We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan. We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances. During the twelve months ended September 30, 2016 the Company raised $300,000 through the issuance of convertible debt and $1,254,751 through the issuance of equity securities. During the three months ended December 31, 2016 the Company raised $240,000 through the issuance of convertible debt and $560,000 through the issuance of equity securities.

As of December 31, 2016 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company’s Principal Executive Officer and Todd S. Caven who is the Company’s Chief Financial Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company’s internal controls during the period commencing on October 1, 2016 and ending on December 31, 2016, David Koos and Todd S. Caven , who serve as the Company’s Principal Executive Officer and Principal Financial Officer respectively, have determined that there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

There are no material pending legal proceedings to which the Company is a party or of which any of the Company’s property is the subject.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Common Stock:

On November 8, 2016 the Company sold 5,000,000 of its Common Shares (“Shares”) for consideration of $112,500.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

On November 9, 2016 the Company sold 500,000 (“Shares”) of its Common Shares for consideration of $12,500.

On December 19, 2016 the Company sold 7,700,000 of its Common Shares (“Shares”) for consideration of $142,500

On January 5, 2017 the Company sold 1,000,000 of its Common Shares (“Shares”) for consideration of $12,500

Series A Preferred Shares

On November 8, 2016 the Company sold 5,000,000 of its Series A Preferred Shares (“Shares”) for consideration of $112,500.

On November 9, 2016 the Company sold 500,000 of its Series A Preferred Shares (“Shares”) for consideration of $12,500.

On December 19, 2016 the Company sold 9,700,000 of its Series A Preferred Shares (“Shares”) for consideration of $ 167,500

On January 5, 2017 the Company sold 1,000,000 of its Series A Preferred Shares (“Shares”) for consideration of $ 12,500

Convertible Notes

The Note was issued pursuant to Section 4(2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Note was sold directly through our management. No commission or other consideration was paid in connection with the sale of the Note. There was no advertisement or general solicitation made in connection with this Offer and Sale of the Note.

The Note contained a provision that until such time as the shares of stock issuable upon conversion of the Note have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, each certificate for shares of stock issuable upon conversion of the Note that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration statement or an exemption that permits removal of the legend, shall bear a restrictive legend.

On October 31, 2016 (“Issue date”) the Company issued a second Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is two years from the issue date.

On December 22, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $40,000 for consideration consisting of $40,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.

Use of Proceeds

With regard to all securities sold for cash consideration described above, Cash proceeds received from sale will be utilized by Regen for general corporate purposes

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

Item 5. OTHER INFORMATION

None

Item 6. EXHIBITS

31.1	Certification of Chief Executive Officer
31.2	Certification of Acting Chief Financial Officer
32.1	Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
10.1	Form of Unit Purchase Agreement $100,000 (a)
10.2	Form of Unit Purchase Agreement $100,000 (b)
10.3	Form of Unit Purchase Agreement $25,000 ( c)
10.4	Form of Unit Purchase Agreement dated 10/25/2016(d)
10.5	Form of Unit Purchase Agreement 3 million Units ( e)
10.6	Form of Unit Purchase Agreement 500,00 Units(f)
10.7	Form of Unit Purchase Agreement 1,500,000 Units (g)
10.8	Form of Unit Purchase 1,750,000 Units (h)
10.9	Convertible Note $50,000
10.10	Convertible Note $50,000
10.11	Convertible Note $50,000
10.12	Convertible Note $50,000
10.13	Convertible Note $40,000
10.14	Form of Unit Purchase Agreement $25,000
10.15	Text of Certificate of Designations Series M Preferred Stock (i)

(a)

Incorporated by reference to Exhibit 10.79 of the Company’s Form 10-K for the year ended September 30, 2016

(b)

Incorporated by reference to Exhibit 10.80 of the Company’s Form 10-K for the year ended September 30, 2016

(c)

Incorporated by reference to Exhibit 10.81 of the Company’s Form 10-K for the year ended September 30, 2016

(d)

Incorporated by reference to Exhibit 10.82 of the Company’s Form 10-K for the year ended September 30, 2016

(e)

Incorporated by reference to Exhibit 10.83 of the Company’s Form 10-K for the year ended September 30, 2016

(f)

Incorporated by reference to Exhibit 10.84 of the Company’s Form 10-K for the year ended September 30, 2016

(g)

Incorporated by reference to Exhibit 10.85 of the Company’s Form 10-K for the year ended September 30, 2016

(h)

Incorporated by reference to Exhibit 10.86 of the Company’s Form 10-K for the year ended September 30, 2016

(i)

Incorporated by reference to Exhibit 3(i) of the Company’s Form 8-K filed January 20, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on January 23, 2017.

			Regen Biopharma, Inc.

	By:		/s/ David R. Koos
	Name:		David R. Koos
	Title:		Principal Executive Officer
	Date:		January 23, 2017

			Regen Biopharma, Inc.

	By:		/s/ David R. Koos
	Name:		David R. Koos
	Title:		Chairman, Director
	Date:		January 23, 2017

			Regen Biopharma, Inc.

	By:		/s/ Todd S. Caven
	Name:		Todd S. Caven
	Title:		Principal Financial Officer
	Date:		January 23, 2017

			Regen Biopharma, Inc.

	By:		/s/ Todd S. Caven
	Name:		Todd S. Koos
	Title:		Principal Accounting Officer
	Date:		January 23, 2017

EX-10.14 2 ex10_4.htm EXHIBIT 10.4

Exhibit 10.14

THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ whose address is _____________.

WHEREAS:

The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set forth herein.

The Company desires to issue and sell Units to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE, IT IS AGREED AS FOLLOWS

Units

Each Unit shall consist of one (1) share of common stock of the Company and one (1) share of the Series A Preferred Stock of the Company

Purchase Price

The purchase price per Unit ( “Purchase Price”), payable in US Dollars, shall be 2.5 cents per unit.(Each Unit consists of one (1) share of common stock of the Company and one (1) shares of the Series A Preferred Stock of the Company)

Form of Payment

The Purchaser shall pay the Purchase Price per Unit multiplied by that number of Units Purchased by wire transfer of immediately available funds to the Company

WIRE INSTRUCTIONS:

Issuance of Units

5 business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Units purchased

Purchaser’s Representations and Warranties

(a)

As of the date hereof, the Purchaser is purchasing the Units for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended ( the “Act”).

(b)

The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Act

(c)

The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Units which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.

(d)

Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(e)

The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.

Company’s representations and warranties

(a)

Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(b)

The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which Company is or may be bound.

Restricted Securities Acknowledgement

Purchaser acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Act , and shall contain the following restrictive legend:

“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

Entire Agreement

This Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations between the parties.

Governing Law, Venue, Waiver Of Jury Trial

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

IN WITNESS WHEREOF, the parties have hereunto executed this Agreement on the 22nd day of December, 2016.

By:

Company



David Koos, CEO
Regen Biopharma, Inc.


Date: December 22, /2016

Purchaser
By:
Its:
Date: December 22, 2016

Number of Units Purchased:	1,000,000
Total Purchase Price:	$25,000

EX-10.9 3 ex10_9.htm EXHIBBIT 10.9

Exhibit 10.9

CONVERTIBLE PROMISSORY NOTE

THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR THE DELIVERY OF AN OPINION OF COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. THIS NOTE IS ALSO SUBJECT TO RESTRICTIONS ON TRANSFER.

Regen BioPharma, Inc.

Issue Date:

October 31 2016

Principal Amount: $50,000

1. Terms. For value received, the Regen BioPharma, Inc., a Nevada corporation (the “Company”) hereby absolutely and unconditionally promises to pay to the order of ________ ON DEMAND any time after October 31, 2018, the principal amount of Fifty Thousand Dollars ($50,000) and interest on the whole amount of said principal sum outstanding and remaining from time to time unpaid (the “Note”), commencing from the date hereof and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate equal to ten percent (10%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section 2 hereunder. Interest shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest shall be payable in lawful money of the United States of America, at the principal place of business of the Lender or at such other place as the Lender may have designated from time to time in writing to the Company.

2. Conversion.

2.1 Conversion Right. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Common Stock and/or Series A Preferred Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock and/or Series A Preferred Stock shall hereafter be changed or reclassified at the conversion price (the “Conversion Price”) determined as provided herein (a “Conversion”). The Lender shall have the right to convert one hundred percent (100%) of the Principal Amount immediately upon execution of this agreement and any accrued interest may be converted as well.

The number of shares of Common Stock and/or Series A Preferred Stock to be issued upon each conversion of this Note shall be determined by dividing the principal amount of this Note to be converted (the “Conversion Amount”) by the applicable Conversion Price as defined in this Section 2 then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the “Notice of Conversion”), delivered to the Company by the Lender on such conversion date (the “Conversion Date”).

2.2 Conversion Price. The “Conversion Price” shall be defined as $0.0125 per share for either the Common and/or the Series A Preferred Stock of the Company

2.3 Method of Conversion. Subject to Section 2.1, this Note may be converted by the Lender by submitting to the Company a Notice of Conversion by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 5:00 p.m., New York, New York time. The Lender shall not be required to physically surrender this Note to the Company unless the entire unpaid principal amount of this Note is so converted. The Lender and the Company shall maintain records showing the principal amount so converted and the dates of such conversions so as not to require physical surrender of this Note upon each such conversion. In the event of any dispute or discrepancy, such records of the Company shall, prima facie, be controlling and determinative in the absence of manifest error. Notwithstanding the foregoing, if any portion of this Note is converted as aforesaid, the Lender may not transfer this Note unless the Lender first physically surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Lender a new Note of like tenor, registered as the Lender (upon payment by the Lender of any applicable transfer taxes) may request, representing in the aggregate the remaining unpaid principal amount of this Note.

Upon receipt by the Company from the Lender of a facsimile transmission, e-mail, or other reasonable means of communication of a Notice of Conversion meeting the requirements for conversion, the Company shall issue and deliver or cause to be issued and delivered to or upon the order of the Lender certificates for the Common Stock and/or Series A Preferred Stock issuable upon such conversion within five (5) business days after such receipt. Upon receipt by the Company of a Notice of Conversion, the Lender shall be deemed to be the Lender of record of the Common Stock and/or Series A Preferred Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion. All rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock and/or Series A Preferred Stock or other securities as herein provided on such conversion. In lieu of delivering physical certificates representing the Common Stock and/or Series A Preferred Stock issuable upon conversion, provided the Company is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”) program, upon request of the Lender, the Company shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock and/or Series A Preferred Stock issuable upon conversion to the Lender by crediting the account of Lender’s Prime Broker with DTC through its Deposit Withdrawal Agent Commission (“DWAC”) system.

2.4 Concerning the Shares. The shares of Common Stock and/or Series A Preferred Stock issuable upon conversion of this Note may not be sold or transferred unless (i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Company or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (iii) such shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Company who agrees to sell or otherwise transfer the shares only in accordance with this Section 2.5 and who is an Accredited Investor as the term Accredited Investor is defined in Rule 501 of Regulation D, promulgated under the Act.

Subject to the removal provisions set forth below, until such time as the shares of Common Stock and/or Series A Preferred Stock issuable upon conversion of this Note have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, each certificate for shares of issuable upon conversion of this Note that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

"NEITHER THE ISSUANCE OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT."

The legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock and/or Series A Preferred Stock may be made without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company or its transfer agent with reasonable assurances that the Common Stock and/or Series A Preferred Stock issuable upon conversion of this Note (to the extent such securities are deemed to have been acquired on the same date) can be sold pursuant to Rule 144 or (iii) in the case of the Common Stock and/or Series A Preferred Stock issuable upon conversion of this Note, such security is registered for sale by under an effective registration statement filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold.

3. Prepayment. Notwithstanding anything to the contrary contained herein, the Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Any notice of prepayment hereunder shall be delivered to the Lender at its registered addresses and shall state that the Company is exercising its right to prepay the Note and the date of prepayment, which shall be not more than three (3) Trading Days from the date of the prepayment notice. Upon receipt of a prepayment notice, Lender shall have the right, but not the obligation, to accelerate the conversion period specified in Section 2.1 and convert that portion of the outstanding principal balance which is subject to prepayment to Common Shares as provided for in Section 2.

4. Events of Default.

4.1 The following shall constitute events of default (individually an "Event of Default"):

(a) default in the payment, when due or payable, of an obligation to pay interest or principal under this Note, which default is not cured by payment in full of the amount due within thirty (30) days from the date that the Lender receives notice of the occurrence of such default;

(b) filing of a petition in bankruptcy or the commencement of any proceedings under any bankruptcy laws by or against the Company, which filing or proceeding, is not dismissed within ninety (90) days after the filing or commencement thereof; or

4.2 If an Event of Default shall occur and be continuing, the Lender may, at its option, declare this Note to be immediately due and payable without further notice or demand, whereupon this Note shall become immediately due and payable without presentment, demand or protest, all of which are hereby waived by the Company.

5. Transfer of Note. This Note may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender. As used herein, the term “Affiliate” means an entity that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Lender.

6. Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any other formalities of any kind.

7. Amendment, Modification or Termination. This Note may only be modified, amended, or terminated (other than by payment in full) by an agreement in writing signed by the Company and the Lender. No waiver of any term, covenant or provision of this Note shall be effective unless given in writing by the Lender.

8. Governing Law. This Note and the obligations of the Company hereunder shall be governed by and interpreted and determined in accordance with the laws of the State of California (excluding the laws and rules of law applicable to conflicts or choice of law).

IN WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA, INC.

	/s/		Dated:
	Chairman and CEO
	________________		10/31/2016
	Purchaser

The foregoing Convertible Promissory Note is hereby accepted and agreed to by the undersigned on and as of the date first above written.

EXHIBIT A

NOTICE OF CONVERSION

The undersigned hereby elects to convert $ _________ principal amount and $____________ accrued interest of the Note into that number of shares of Common Stock and/or Series A Preferred Stock to be issued pursuant to the conversion of the Note as set forth below of REGEN BIOPHARMA, INC. according to the conditions of the convertible note of the Company dated as of MONTH DAY, 201X as of the date written below.

Date of Conversion:
Applicable Conversion Price:
(Attached Bloomberg price documentation)
Number of Shares of Common Stock to be Issued Pursuant to Conversion of the Note:
Number of Shares of Series A Preferred Stock to be Issued Pursuant to Conversion of the Note: _________________________ Amount of Principal Balance Due Remaining Under the Note After This Conversion:

Checked box corresponds to applicable instructions:

☐ The Borrower shall electronically transmit the Common Stock and/or Series A Preferred Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”).

Name of DTC Prime Broker:
Account Number:

☐ The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock and/or Series A Preferred Stock set forth below in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

Name:
Address:


Phone:

XXXXXXXXXXXXXXX, LLC
XXXXXXX		Date

EX-10.10 4 ex10_10.htm EXHIBIT 10.10

Exhibit 10.10

CONVERTIBLE PROMISSORY NOTE

Regen BioPharma, Inc.

Issue Date:

October 7 2016

Principal Amount: $50,000

1. Terms. For value received, the Regen BioPharma, Inc., a Nevada corporation (the “Company”) hereby absolutely and unconditionally promises to pay to the order of ________ ON DEMAND any time after October 7, 2018, the principal amount of Fifty Thousand Dollars ($50,000) and interest on the whole amount of said principal sum outstanding and remaining from time to time unpaid (the “Note”), commencing from the date hereof and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate equal to ten percent (10%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section 2 hereunder. Interest shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest shall be payable in lawful money of the United States of America, at the principal place of business of the Lender or at such other place as the Lender may have designated from time to time in writing to the Company.

2. Conversion.

2.2 Conversion Price. The “Conversion Price” shall be defined as $0.0125 per share for either the Common and/or the Series A Preferred Stock of the Company

4. Events of Default.

4.1 The following shall constitute events of default (individually an "Event of Default"):

6. Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any other formalities of any kind.

IN WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA, INC.

	/s/		Dated:
	Chairman and CEO
	________________		10/7/2016

Purchaser

The foregoing Convertible Promissory Note is hereby accepted and agreed to by the undersigned on and as of the date first above written.

EXHIBIT A

NOTICE OF CONVERSION

Date of Conversion:
Applicable Conversion Price:
(Attached Bloomberg price documentation)
Number of Shares of Common Stock to be Issued Pursuant to Conversion of the Note:
Number of Shares of Series A Preferred Stock to be Issued Pursuant to Conversion of the Note: _________________________ Amount of Principal Balance Due Remaining Under the Note After This Conversion:

Checked box corresponds to applicable instructions:

Name of DTC Prime Broker:
Account Number:

Name:
Address:


Phone:

XXXXXXXXXXXXXXX, LLC
XXXXXXX		Date

EX-10.11 5 ex10_11.htm EXHIBIT 10.11

Exhibit 10.11

CONVERTIBLE PROMISSORY NOTE

Regen BioPharma, Inc.

Issue Date:

October 31 2016

Principal Amount: $50,000

2. Conversion.

2.2 Conversion Price. The “Conversion Price” shall be defined as $0.0125 per share for either the Common and/or the Series A Preferred Stock of the Company

4. Events of Default.

4.1 The following shall constitute events of default (individually an "Event of Default"):

6. Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any other formalities of any kind.

IN WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA, INC.

	/s/		Dated:
	Chairman and CEO
	________________		10/31/2016

Purchaser

The foregoing Convertible Promissory Note is hereby accepted and agreed to by the undersigned on and as of the date first above written.

EXHIBIT A

NOTICE OF CONVERSION

Date of Conversion:
Applicable Conversion Price:
(Attached Bloomberg price documentation)
Number of Shares of Common Stock to be Issued Pursuant to Conversion of the Note:
Number of Shares of Series A Preferred Stock to be Issued Pursuant to Conversion of the Note: _________________________ Amount of Principal Balance Due Remaining Under the Note After This Conversion:

Checked box corresponds to applicable instructions:

Name of DTC Prime Broker:
Account Number:

Name:
Address:


Phone:

XXXXXXXXXXXXXXX, LLC
XXXXXXX		Date

EX-10.12 6 ex10_12.htm EXHIBIT 10.12

Exhibit 10.12

CONVERTIBLE PROMISSORY NOTE

Regen BioPharma, Inc.

Issue Date:

October 31 2016

Principal Amount: $50,000

2. Conversion.

2.2 Conversion Price. The “Conversion Price” shall be defined as $0.0125 per share for either the Common and/or the Series A Preferred Stock of the Company

4. Events of Default.

4.1 The following shall constitute events of default (individually an "Event of Default"):

6. Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any other formalities of any kind.

IN WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA, INC.

	/s/		Dated:
	Chairman and CEO
	________________		10/31/2016

Purchaser

The foregoing Convertible Promissory Note is hereby accepted and agreed to by the undersigned on and as of the date first above written.

EXHIBIT A

NOTICE OF CONVERSION

Date of Conversion:
Applicable Conversion Price:
(Attached Bloomberg price documentation)
Number of Shares of Common Stock to be Issued Pursuant to Conversion of the Note:
Number of Shares of Series A Preferred Stock to be Issued Pursuant to Conversion of the Note: _________________________ Amount of Principal Balance Due Remaining Under the Note After This Conversion:

Checked box corresponds to applicable instructions:

Name of DTC Prime Broker:
Account Number:

Name:
Address:


Phone:

XXXXXXXXXXXXXXX, LLC
XXXXXXX		Date

EX-10.13 7 ex10_13.htm EXHIBIT 10.13

Exhibit 10.13

CONVERTIBLE PROMISSORY NOTE

Regen BioPharma, Inc.

Issue Date:

December 22 2016

Principal Amount: $40,000

1. Terms. For value received, the Regen BioPharma, Inc., a Nevada corporation (the “Company”) hereby absolutely and unconditionally promises to pay to the order of ________ ON DEMAND any time after December 22 , 2017, the principal amount of Forty Thousand Dollars ($50,000) and interest on the whole amount of said principal sum outstanding and remaining from time to time unpaid (the “Note”), commencing from the date hereof and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate equal to ten percent (10%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section 2 hereunder. Interest shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest shall be payable in lawful money of the United States of America, at the principal place of business of the Lender or at such other place as the Lender may have designated from time to time in writing to the Company.

2. Conversion.

2.2 Conversion Price. The “Conversion Price” shall be defined as $0.01 per share for either the Common and/or the Series A Preferred Stock of the Company

4. Events of Default.

4.1 The following shall constitute events of default (individually an "Event of Default"):

6. Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any other formalities of any kind.

IN WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.

	REGEN BIOPHARMA, INC.

	/s/		Dated:
	Chairman and CEO
	________________		12/22/2016

Purchaser

The foregoing Convertible Promissory Note is hereby accepted and agreed to by the undersigned on and as of the date first above written.

EXHIBIT A

NOTICE OF CONVERSION

Date of Conversion:
Applicable Conversion Price:
(Attached Bloomberg price documentation)
Number of Shares of Common Stock to be Issued Pursuant to Conversion of the Note:
Number of Shares of Series A Preferred Stock to be Issued Pursuant to Conversion of the Note: _________________________ Amount of Principal Balance Due Remaining Under the Note After This Conversion:

Checked box corresponds to applicable instructions:

Name of DTC Prime Broker:
Account Number:

Name:
Address:


Phone:

XXXXXXXXXXXXXXX, LLC
XXXXXXX		Date

EX-10.14 8 ex10_14.htm EXHIBIT 10.14

Exhibit 10.14

WHEREAS:

The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set forth herein.

The Company desires to issue and sell Units to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE, IT IS AGREED AS FOLLOWS

Units

Each Unit shall consist of one (1) share of common stock of the Company and one (1) share of the Series A Preferred Stock of the Company

Purchase Price

Form of Payment

The Purchaser shall pay the Purchase Price per Unit multiplied by that number of Units Purchased by wire transfer of immediately available funds to the Company

WIRE INSTRUCTIONS:

Issuance of Units

5 business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Units purchased

Purchaser’s Representations and Warranties

(a)

(b)

The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Act

(c)

(d)

(e)

Company’s representations and warranties

(a)

(b)

Restricted Securities Acknowledgement

Entire Agreement

Governing Law, Venue, Waiver Of Jury Trial

IN WITNESS WHEREOF, the parties have hereunto executed this Agreement on the 22nd day of December, 2016.

By:

Company



David Koos, CEO
Regen Biopharma, Inc.


Date: December 22, /2016

Purchaser
By:
Its:
Date: December 22, 2016

Number of Units Purchased:	1,000,000
Total Purchase Price:	$25,000

EX-31.1 9 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Koos, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Regen BioPharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 23, 2017	By:	/s/ David R. Koos
		David R. Koos Chief Executive Officer

EX-31.2 10 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF ACTING CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Todd S. Caven, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Regen BioPharma, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 23, 2017	By:	/s/ Todd S. Caven
		Todd S. Caven Acting Chief Financial Officer

EX-32.1 11 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly report of Regen BioPharma, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: January 23, 2017	By:	/s/ David R. Koos
		David R. Koos Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Regen BioPharma, Inc. and will be retained by Regen BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request

EX-32.2 12 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: January 23, 2017	By:	/s/ Todd S. Caven
		Todd S. Caven Acting Chief Financial Officer

EX-101.INS 13 rgbp-20161231.xml XBRL INSTANCE FILE 0001589150 2016-09-30 0001589150 2016-10-01 2016-12-31 0001589150 2015-10-01 2015-12-31 0001589150 2012-04-24 2016-12-31 0001589150 2016-12-31 0001589150 us-gaap:SeriesAPreferredStockMember RGBP:TransactionMember 2016-12-31 0001589150 us-gaap:SeriesAPreferredStockMember 2016-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2016-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2016-09-30 0001589150 RGBP:DavidKoosMember 2015-10-01 2015-12-31 0001589150 RGBP:DavidKoosMember 2016-12-31 0001589150 us-gaap:CommonStockMember 2016-10-01 2016-12-31 0001589150 us-gaap:CommonStockMember 2016-11-08 0001589150 us-gaap:CommonStockMember 2016-11-09 0001589150 us-gaap:CommonStockMember 2016-12-19 0001589150 us-gaap:SeriesAPreferredStockMember 2017-01-05 0001589150 RGBP:BostoniaPartnersMember 2016-12-31 0001589150 RGBP:BostoniaPartnersMember 2016-10-01 2016-12-31 0001589150 RGBP:BostoniaPartners2Member 2016-10-01 2016-12-31 0001589150 RGBP:BostoniaPartners2Member 2016-12-31 0001589150 RGBP:EntestBiomedicalIncMember 2015-12-31 0001589150 RGBP:EntestBiomedicalIncMember 2015-10-01 2015-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2015-10-01 2015-12-31 0001589150 us-gaap:SeriesAPreferredStockMember RGBP:Transaction2Member 2016-11-09 0001589150 2015-09-30 0001589150 2016-03-08 0001589150 2016-04-06 0001589150 2016-08-26 0001589150 2016-09-08 0001589150 2016-09-20 0001589150 2015-10-01 2016-04-06 0001589150 2015-10-01 2016-03-08 0001589150 2015-10-01 2016-08-26 0001589150 2015-10-01 2016-09-08 0001589150 2015-10-01 2016-09-20 0001589150 2016-10-01 2016-10-31 0001589150 2016-10-07 0001589150 2016-10-01 2016-10-07 0001589150 us-gaap:ConvertibleNotesPayableMember 2016-10-31 0001589150 us-gaap:ConvertibleNotesPayableMember 2016-10-01 2016-10-31 0001589150 RGBP:ConvertibleNotesPayable2Member 2016-10-31 0001589150 RGBP:ConvertibleNotesPayable2Member 2016-10-01 2016-10-31 0001589150 RGBP:ConvertibleNotesPayable3Member 2016-10-31 0001589150 RGBP:ConvertibleNotesPayable3Member 2016-10-01 2016-10-31 0001589150 2016-12-22 0001589150 2016-10-01 2016-12-22 0001589150 RGBP:DavidKoosMember 2015-10-01 2016-09-30 0001589150 2016-07-01 2016-09-30 0001589150 2015-09-28 0001589150 us-gaap:SeriesAPreferredStockMember RGBP:TransactionMember 2016-10-01 2016-12-31 0001589150 us-gaap:SeriesAPreferredStockMember us-gaap:ChiefFinancialOfficerMember 2016-10-01 2016-12-31 0001589150 us-gaap:CommonStockMember 2017-01-05 0001589150 RGBP:SeriesMPreferredStockMember 2017-01-10 0001589150 us-gaap:CommonStockMember us-gaap:ChiefFinancialOfficerMember 2016-10-01 2016-12-31 0001589150 RGBP:Transaction2Member 2016-10-01 2016-11-09 0001589150 RGBP:Transaction3Member 2016-12-19 0001589150 RGBP:Transaction3Member 2016-10-01 2016-12-19 0001589150 us-gaap:SeriesAPreferredStockMember 2016-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 145412605

24822

220718

12051

2578

2878

207356

394658

319356

706658

240759

163927

143447

68638

33040

3677

43918

54841

15000 20000

263996

349496

799201

733004

906258

862779

13970

14540

12500

112500

12500

142500

12500

13527 14797 3 3

18961259

21714779

728658

-20224319

-22748898

-586902

-156121

319356

706658

0.0001

500000000

139712605

5000000

500000

7700000

1000000

139712605

145412605

42694

105323

242758

488596

233128

80533

15000

533580

689452

-533580

-689452

300

11923

5001

1950120 1163313

-1990999

-1168014

-2524579

-1857466

-0.018

-0.0157

143596121

118216582

-76832

1792

72060

25495

-74809

-54701

5240

247723

700191

555300

195896

129897

24822

38620

NOTE 10. STOCKHOLDERS EQUITY   The stockholders equity section of the Company contains the following classes of capital stock as of December 31, 2016:   Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 145,412,605 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Companys stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of December 31, 2016 and 300,000,000 is designated Series A Preferred Stock of which 147,966,697 shares are outstanding as of December 31, 2016. The abovementioned shares authorized pursuant to the Companys certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock   On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (Certificate of Designations) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Series AA Preferred Stock (hereinafter referred to as Series AA Preferred Stock).   The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.   Series A Preferred Stock   On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (Certificate of Designations) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Series A Preferred Stock (hereinafter referred to as Series A Preferred Stock). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the Board) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the Additional Dividends) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a Liquidation), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the Liquidation Amount) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

143447

68638

68588

7734625

22748898

728658

50010000 20090 5000

.0001

0.0001

100000000

800000000

300000000

600000

300000000

69905

61011

139712605

30000

1000000

500000

9700000

147966697

139712605

30000

147966697

8894

9000

1.00

240000

0.10

.01

Regen BioPharma Inc 0001589150 10-Q 2016-12-31 false --09-30 No No Yes Smaller Reporting Company Q1 2017 50000 25000

-80000

120000

200000

-38400

200000

-38400

-2324579

-1895866

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a controlled subsidiary of Bio-Matrix Scientific Group, Inc, (BMSN) a Delaware corporation.   The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials   A. BASIS OF ACCOUNTING   The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.   B. USE OF ESTIMATES   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   C. CASH EQUIVALENTS   The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.     D. PROPERTY AND EQUIPMENT   Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.   E. FAIR VALUE OF FINANCIAL INSTRUMENTS   Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:   Level 1:  Quoted prices in active markets for identical assets or liabilities   Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.   Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.   F. INCOME TAXES   The Company accounts for income taxes using the liability method prescribed by ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.   The Company applied the provisions of ASC 740-10-50, Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Companys liability for income taxes. Any such adjustment could be material to the Companys results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.   The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.   Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.   G.  BASIC EARNINGS (LOSS) PER SHARE   The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, Earnings Per Share, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.   Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.   H. ADVERTISING   Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .   I. REVENUE RECOGNITION   Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Companys estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensees sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a controlled subsidiary of Bio-Matrix Scientific Group, Inc, (BMSN) a Delaware corporation.   The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials   A. BASIS OF ACCOUNTING   The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.   B. USE OF ESTIMATES   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   C. CASH EQUIVALENTS   The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.     D. PROPERTY AND EQUIPMENT   Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.   E. FAIR VALUE OF FINANCIAL INSTRUMENTS   Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:   Level 1:  Quoted prices in active markets for identical assets or liabilities   Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.   Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.   F. INCOME TAXES   The Company accounts for income taxes using the liability method prescribed by ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.   The Company applied the provisions of ASC 740-10-50, Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Companys liability for income taxes. Any such adjustment could be material to the Companys results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.   The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.   Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.   G.  BASIC EARNINGS (LOSS) PER SHARE   The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, Earnings Per Share, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.   Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.   H. ADVERTISING   Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .   I. REVENUE RECOGNITION   Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Companys estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensees sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

A. BASIS OF ACCOUNTING   The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. USE OF ESTIMATES   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS   The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT   Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

E. FAIR VALUE OF FINANCIAL INSTRUMENTS   Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:   Level 1:  Quoted prices in active markets for identical assets or liabilities   Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.   Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES   The Company accounts for income taxes using the liability method prescribed by ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.   The Company applied the provisions of ASC 740-10-50, Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Companys liability for income taxes. Any such adjustment could be material to the Companys results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.   The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.   Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G.  BASIC EARNINGS (LOSS) PER SHARE   The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.   Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING   Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .

NOTE 2.  RECENT ACCOUNTING PRONOUNCEMENTS   In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as Development Stage Entities (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entitys financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.   The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.   In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation Stock Compensation. As a result, the target is not reflected in the estimation of the awards grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entitys liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entitys liquidation becomes imminent, financial statements should be prepared   under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial StatementsLiquidation Basis of Accounting. Even when an entitys liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entitys ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.   On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.   On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:   The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.   Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.   While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Companys operating results or financial position.   On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Companys operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Companys management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 22,748,898 during the period from April 24, 2012 (inception) through December 31, 2016. This condition raises substantial doubt about the Companys ability to continue as a going concern. The Companys continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the year ended September 30, 2016 the Company raised $1,254,751 through the issuance of equity securities for cash and $300,000 through the issuance of convertible debentures. During the quarter ended December 31, 2016 the Company raised $585,000 through the issuance of equity securities for cash and $240,000 through the issuance of convertible debentures.

NOTE 4. NOTES PAYABLE   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">David Koos ( Note 8)</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">50</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Bostonia Partners</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">68,588</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-indent: -0.25in">Notes payable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">68,638</td> <td style="padding-bottom: 1pt"> </td></tr> </table>      $50 lent to the Company by David Koos. is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.   $5,288 lent to the Company by Bostonia Partners is due and payable March 8, 2017 and bears simple interest at a rate of 10% per annum.   $63,300 lent to the Company by Bostonia Partners is due and payable May 10 2017 and bears simple interest at a rate of 10% per annum.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">David Koos ( Note 8)</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">50</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Bostonia Partners</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">68,588</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt; padding-left: 20pt; text-indent: -0.25in">Notes payable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">68,638</td> <td style="padding-bottom: 1pt"> </td></tr> </table>

5288

63300

2017-03-08

2017-05-10

NOTE 6. NOTES RECEIVABLE   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: Silver"> <td style="width: 72%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Entest Biomedical, Inc. (Note 8)</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">12,051</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-indent: -0.25in">Notes Receivable</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">12,051</td> <td> </td></tr> </table>    $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 72%; padding-left: 20pt; text-align: justify; text-indent: -0.25in">Entest Biomedical, Inc. (Note 8)</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">12,051</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; text-align: justify; text-indent: -0.25in"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 20pt; text-indent: -0.25in">Notes Receivable</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">12,051</td> <td> </td></tr> </table>

12051

NOTE 7. INCOME TAXES   As of December 31, 2016   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="text-align: justify">Deferred tax assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; text-align: justify">Net operating tax carry forwards</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">7,</td> <td style="width: 1%">734,625 </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="text-align: justify">Other</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-0-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Gross deferred tax assets</td> <td> </td> <td> </td> <td style="text-align: right">7,734,625</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="text-align: justify">Valuation allowance</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(7,734,625)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Net deferred tax assets</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-0-</td> <td> </td></tr> </table>   As of December 31, 2016 the Company has a Deferred Tax Asset of $7,734,625completely attributable to net operating loss carry forwards of approximately $22,748,898 (which expire 20 years from the date the loss was incurred).   Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to 0.   Income tax is calculated at the 34% Federal Corporate Rate.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="text-align: justify">Deferred tax assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 73%; text-align: justify">Net operating tax carry forwards</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">7,734,625</td> </tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="text-align: justify">Other</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-0-</td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Gross deferred tax assets</td> <td> </td> <td> </td> <td style="text-align: right">7,734,625</td> </tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="text-align: justify">Valuation allowance</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(7,734,625)</td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Net deferred tax assets</td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-0-</td> </tr> </table>

0.34

NOTE 8. RELATED PARTY TRANSACTIONS   As of December 31, 2016 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (BMSN) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.   The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Companys parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.   As of December 31, 2016 Entest Biomedical Inc. is indebted to the Company in the amount of $12,051. $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.    As of December 31, 2016 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.   On June 23, 2015 the Company entered into an agreement (Agreement) with Zander Therapeutics, Inc. ( Zander) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company ( License IP) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a wholly owned subsidiary of Entest Biomedical, Inc.   Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.   The abovementioned payments may be made, at Zanders discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance.   Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.   Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).   Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).   The Agreement may be terminated by The Company:   If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zanders first commercial sale of a Licensed Product.   The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.   The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated.   The Agreement may be terminated by either party in the event of a material breach by the other party.   On September 28, 2015 Zander caused to be issued to the Company 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to the Company by Zander as a license initiation fee. Regen Biopharma, Inc. recognized revenue of $192,000 equivalent to the fair value of 8,000,000 of the common shares of Entest Biomedical, Inc as of the date of issuance. During the quarter ended September 30, 2016 Zander paid $17,000 to the Company as a partial payment of the July 15th, 2016 liability David R. Koos serves as sole officer and director of both Zander and Entest Biomedical, Inc. and also serves as Chairman and Chief Executive Officer of The Company.

100000

17000

0.04

10000

8000000

NOTE 9. COMMITMENTS AND CONTINGENCIES   The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Companys parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.

Series A Preferred Stock   On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (Certificate of Designations) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Series A Preferred Stock (hereinafter referred to as Series A Preferred Stock). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the Board) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the Additional Dividends) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a Liquidation), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the Liquidation Amount) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000).

NOTE 12. STOCK TRANSACTIONS   Common Stock   On November 8, 2016 the Company sold 5,000,000 of its Common Shares for consideration of $112,500.   On November 9, 2016 the Company sold 500,000 of its Common Shares for consideration of $12,500.   On December 19, 2016 the Company sold 7,700,000 of its Common Shares for consideration of $142,500   Series A Preferred Stock   On November 8, 2016 the Company sold 5,000,000 of its Series A Preferred Shares for consideration of $112,500.   n November 9, 2016 the Company sold 500,000 of its Series A Preferred Shares for consideration of $12,5000   On December 19, 2016 the Company sold 9,700,000 of its Series A Preferred Shares for consideration of $ 167,500   Cancellation of Officer Shares   On December 27, 2016 Todd Caven, the Companys Chief Financial Officers, agreed to the cancellation of 7,500,000 of his personally owned Common Shares of the Company. No consideration was paid to Mr. Caven for this cancellation.   On December 30, 2016 Todd Caven, the Companys Chief Financial Officers, agreed to the cancellation of 2,500,000 of his personally owned Series A Preferred Shares of the Company. No consideration was paid to Mr. Caven for this cancellation.

12500

15000 15000

112000

312000

112000

312000

0 -15000 -25000 50000

-504295

-425403

112500

12500

167500

83000

9041

47425

107057

129776

107057 129776

31846

61102

1950120 1163313

-300

0 0

1000

I. REVENUE RECOGNITION   Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Companys estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensees sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

1254751

300000

NOTE 5. CONVERTIBLE NOTES PAYABLE   On March 8, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:   (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (Year 1) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (Year 2) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (Year 3) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (d) Trading Price means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the OTCQB) as reported by a reliable reporting service (Reporting Service) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the pink sheets by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. Trading Day shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. Trading Volume shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lenders securities.   The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.   Transaction Event shall mean either of:   (a) The sale by the Company of the Companys proprietary NR2F6 intellectual property to an unaffiliated third party   (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Companys proprietary NR2F6 intellectual property   The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible notes outstanding is $ 34,625. As of September 30, 2016 $100,000 of the principal amount of the Note remains outstanding.   The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is $25,000.   On April 6, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:   (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (Year 1) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (Year 2) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (Year 3) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (d) Trading Price means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the OTCQB) as reported by a reliable reporting service (Reporting Service) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the pink sheets by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. Trading Day shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. Trading Volume shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lenders securities.   The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.   Transaction Event shall mean either of:   (a) The sale by the Company of the Companys proprietary NR2F6 intellectual property to an unaffiliated third party   (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Companys proprietary NR2F6 intellectual property   The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 8,317. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is $12,500.   On August 26, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 45,205. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">(a)</td> <td style="text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>   On September 8, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 47,123. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(a)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>   On September 20, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 48,630. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.   The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(a)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>

100000

50000

40000

0.08

0.10

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 45,205. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(a)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (Year 1) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (Year 2) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (Year 3) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).   (d) Trading Price means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the OTCQB) as reported by a reliable reporting service (Reporting Service) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the pink sheets by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. Trading Day shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. Trading Volume shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lenders securities.   The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.   Transaction Event shall mean either of:   (a) The sale by the Company of the Companys proprietary NR2F6 intellectual property to an unaffiliated third party   (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Companys proprietary NR2F6 intellectual property

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 45,205. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(a)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>   On September 8, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 47,123. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(a)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>   On September 20, 2016 (Issue date) the Company issued a Convertible Note (Note) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.   The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.   The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.   The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 48,630. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.   The amount by which the Notes as converted value exceeds the principal amount as of September 30, 2016 is :   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(a)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$450,000 if the entire principal amount is converted into common stock</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif">(b)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">$430,000 if the entire principal amount is converted into Series A Preferred stock</td></tr> </table>

9900

42600

50000

40000

31085

7495

32739

34657

36164

44178

45821

39013

192000

11. INVESTMENT SECURITIES On September 28, 2015 Zander Theraputics, Inc. caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander Theraputics, Inc as a license initiation fee. The common shares of Entest Biomedical, Inc described above constitute the Companys sole investment securities as of December 31, 2016. As of December 31, 2016: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: right">8,000,000</td> <td> </td> <td colspan="2"> </td> <td colspan="5">Common Shares of Entest Biomedical, Inc.</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Basis</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Fair Value</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Total Unrealized Gains in Other Comprehensive Income  </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter  ended December 31, 2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>$</td> <td style="text-align: right">192,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">$312,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">120,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td></tr> </table>

192000

120000

200000

8000000 100000 8000000

2500000

7500000

NOTE 13. CHANGES AFFECTING COMPARIBILITY   Within the Companys Statement of Cash Flows for the Quarters Ended December 31, 2015 and 2016 the line item entitled Increase (Decrease) in Additional paid in Capital which represents Restricted Stock Award compensation expense recognized for the periods on Restricted Stock Awards issued to employees is presented as an adjustment to reconcile net loss to net cash used in operating activities. The Companys previously released Statement of Cash Flows for the Quarter Ended December 31, 2015 presented the same line item as a financing activity. Management has determined that such presentation does not best reflect the nature of the expense incurred and has adjusted the prior period accordingly.

NOTE 14. SUBSEQUENT EVENTS   On January 5, 2017 the Company sold 1,000,000 of its Common Shares for consideration of $12,500   On January 5, 2017 the Company sold 1,000,000 of its Series A Preferred Shares for consideration of $ 12,500   On January 10, 2017 Regen Biopharma, Inc. (Regen) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The Board of Directors of Regen have authorized 300,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regens stockholders, a ratable share in the assets of Regen.

267500 321667 292500 238334 -2524579 -22748898 220718 168517

EX-101.SCH 14 rgbp-20161231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes Receivable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stock Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Changes Affecting Comparibility link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Notes Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes Payable and Convertible Notes Payable - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Receivable - Notes Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Income Taxes - Deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stockholders Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Investment Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Investment Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stock Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 rgbp-20161231_cal.xml XBRL CALCULATION FILE EX-101.DEF 16 rgbp-20161231_def.xml XBRL DEFINITION FILE EX-101.LAB 17 rgbp-20161231_lab.xml XBRL LABEL FILE Series A Preferred Stock Class of Stock [Axis] Transaction #1 Nonmonetary Transaction Type [Axis] Series AA Preferred Stock David Koos Debt Instrument [Axis] Common Stock Bostonia Partners Bostonia Partners 2 Entest Biomedical, Inc Transaction #2 Convertible Notes Payable Convertible Notes Payable #2 Convertible Notes Payable #3 Todd Caven Class of Stock [Axis] Equity Components [Axis] Series M Preferred Stock Transaction #3 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Accounts Receivable Note Receivable Prepaid Expenses Accrued Interest Receivable Due from Former Employees Total Current Assets OTHER ASSETS Available for Sale Securities Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Bank Overdraft Accounts payable Notes Payable Accrued payroll taxes Accrued Interest Accrued Rent Accrued Payroll Due to Shareholder Convertible Notes Payable Total Current Liabilities Long Term Liabilities: Convertible Notes Payable Total Long Term Liabilities Total Liabilities STOCKHOLDERS EQUITY (DEFICIT) Common Stock ($.0001 par value) 500,000,000 shares authorized; 145412605 issued and outstanding as of December 31, 2016 and 139,712,605 shares issuedand outstanding September 30, 2016 Series A Preferred 300,000,000 authorized, 147,966,697 and 135,266,697 outstanding as of December 31, 2016 and September 30, 2016 respectively Series AA Preferred $0.0001 par value 600,000 authorized and 30,000 outstanding as of December 31, 2016 and September 30, 2016 Additional Paid in capital Contributed Capital Retained Earnings (Deficit) accumulated during the development stage Accumulated other comprehensive income Total Stockholders' Equity (Deficit) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Income Statement [Abstract] REVENUES COST AND EXPENSES Research and Development General and Administrative Consulting and Professional Fees Rent Total Costs and Expenses OPERATING LOSS OTHER INCOME & (EXPENSES) Interest Income Other Income Refunds of amounts previously paid Interest Expense Interest Expense attributable to Amortization of Discount Loss on issuance of common shares for less than fair value Preferred shares issued pursuant to contractual obligations TOTAL OTHER INCOME (EXPENSE) NET INCOME (LOSS) BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Statement Of Comprehensive Income Net Income (Loss) Add: Unrealized Gains on Securities Less: Unrealized Losses on Securities Total Other Comprehensive Income (Loss) Comprehensive Income Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net Income to net cash Stock Received as Payment for Services Preferred Stock issued for Expenses Preferred Stock issued for Compensation Preferred Stock issued for Interest Preferred Stock issued pursuant to contractual obligations Common Stock issued to Consultants Preferred Stock issued to Consultants Increase (Decrease) in Interest expense attributable to amortization of Discount Increase in inssuance of stock below fair value Increase in Additional Paid in Capital Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable (Increase) Decrease in Accounts Receivable (Increase) Decrease in Notes Receivable (Increase) Decrease in Interest Receivable Increase (Decrease) in Bank Overdraft Increase (Decrease) in Accrued Expenses (Increase) Decrease in Prepaid Expenses (Increase) Decrease in Due from Former Employee Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM FINANCING ACTIVITIES Common Stock issued for Cash Preferred Stock issued for Cash Increase in Contributed Capital Increase (Decrease) in Notes Payable Increase in Convertible Notes Payable Increase (Decrease) in Due to Shareholder Net Cash Provided by (Used in) Financing Activities Net Increase (Decrease) in Cash Cash at Beginning of Period Cash at End of Period Supplemental Disclosure of Noncash Investing and Financing Activities: Common Shares Issued for Debt Preferred Shares Issued for Debt Cash Paid for Interest Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Debt Disclosure [Abstract] Notes Payable Convertible Notes Payable Receivables [Abstract] Notes Receivable Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Stockholders Equity Investment Securities Notes to Financial Statements Stock Transactions Changes Affecting Comparibility Subsequent Events [Abstract] Subsequent Events BASIS OF ACCOUNTING USE OF ESTIMATES CASH EQUIVALENTS PROPERTY AND EQUIPMENT FAIR VALUE OF FINANCIAL INSTRUMENTS INCOME TAXES BASIC EARNINGS (LOSS) PER SHARE ADVERTISING REVENUE RECOGNITION Notes Payable Notes Receivable Deferred tax assets Comprehensive Income Advertising expenses EX-101.PRE 18 rgbp-20161231_pre.xml XBRL PRESENTATION FILE XML 19 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Dec. 31, 2016 shares
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	0001589150
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	145,412,605
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2017

XML 20 R2.htm IDEA: XBRL DOCUMENT

Balance Sheet (Unaudited) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
CURRENT ASSETS
Cash	$ 220,718	$ 24,822
Accounts Receivable	83,000	83,000
Note Receivable	12,051	12,051
Prepaid Expenses	61,011	69,905
Accrued Interest Receivable	2,878	2,578
Due from Former Employees	15,000	15,000
Total Current Assets	394,658	207,356
OTHER ASSETS
Available for Sale Securities	312,000	112,000
Total Other Assets	312,000	112,000
TOTAL ASSETS	706,658	319,356
Current Liabilities:
Bank Overdraft	0	0
Accounts payable	163,927	240,759
Notes Payable	68,638	143,447
Accrued payroll taxes	3,677	33,040
Accrued Interest	54,841	43,918
Accrued Rent	20,000	15,000
Accrued Payroll	349,496	263,996
Due to Shareholder	25,000	50,000
Convertible Notes Payable	47,425	9,041
Total Current Liabilities	733,004	799,201
Long Term Liabilities:
Convertible Notes Payable	129,776	107,057
Total Long Term Liabilities	129,776	107,057
Total Liabilities	862,779	906,258
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 145412605 issued and outstanding as of December 31, 2016 and 139,712,605 shares issuedand outstanding September 30, 2016	14,540	13,970
Series A Preferred 300,000,000 authorized, 147,966,697 and 135,266,697 outstanding as of December 31, 2016 and September 30, 2016 respectively	14,797	13,527
Series AA Preferred $0.0001 par value 600,000 authorized and 30,000 outstanding as of December 31, 2016 and September 30, 2016	3	3
Additional Paid in capital	21,714,779	18,961,259
Contributed Capital	728,658	728,658
Retained Earnings (Deficit) accumulated during the development stage	(22,748,898)	(20,224,319)
Accumulated other comprehensive income	120,000	(80,000)
Total Stockholders' Equity (Deficit)	(156,121)	(586,902)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 706,658	$ 319,356

XML 21 R3.htm IDEA: XBRL DOCUMENT

Balance Sheet (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2016	Sep. 30, 2016
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued		139,712,605
Common stock, shares outstanding	145,412,605	139,712,605
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, shares authorized	800,000,000	100,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued	147,966,697	139,712,605
Preferred stock, shares outstanding	147,966,697	139,712,605
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	30,000	30,000
Preferred stock, shares outstanding	30,000	30,000

XML 22 R4.htm IDEA: XBRL DOCUMENT

Statement of Operations (Unaudited) - USD ($)	3 Months Ended
Statement of Operations (Unaudited) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
REVENUES	$ 0	$ 0
COST AND EXPENSES
Research and Development	42,694	105,323
General and Administrative	242,758	488,596
Consulting and Professional Fees	233,128	80,533
Rent	15,000	15,000
Total Costs and Expenses	533,580	689,452
OPERATING LOSS	(533,580)	(689,452)
OTHER INCOME & (EXPENSES)
Interest Income	300	300
Other Income	31,846
Refunds of amounts previously paid
Interest Expense	(11,923)	(5,001)
Interest Expense attributable to Amortization of Discount	(61,102)
Loss on issuance of common shares for less than fair value	(1,950,120)	(1,163,313)
Preferred shares issued pursuant to contractual obligations
TOTAL OTHER INCOME (EXPENSE)	(1,990,999)	(1,168,014)
NET INCOME (LOSS)	$ (2,524,579)	$ (1,857,466)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.018)	$ (0.0157)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	143,596,121	118,216,582

XML 23 R5.htm IDEA: XBRL DOCUMENT

Statement of Comprehensive Income (Unaudited) - USD ($)	3 Months Ended
Statement of Comprehensive Income (Unaudited) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Statement Of Comprehensive Income
Net Income (Loss)	$ (2,524,579)	$ (1,857,466)
Add:
Unrealized Gains on Securities	200,000
Less:
Unrealized Losses on Securities		(38,400)
Total Other Comprehensive Income (Loss)	200,000	(38,400)
Comprehensive Income	$ (2,324,579)	$ (1,895,866)

XML 24 R6.htm IDEA: XBRL DOCUMENT

Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
Statement of Cash Flows (Unaudited) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (2,524,579)	$ (1,857,466)
Adjustments to reconcile net Income to net cash
Stock Received as Payment for Services
Preferred Stock issued for Expenses
Preferred Stock issued for Compensation
Preferred Stock issued for Interest
Preferred Stock issued pursuant to contractual obligations
Common Stock issued to Consultants
Preferred Stock issued to Consultants		40
Increase (Decrease) in Interest expense attributable to amortization of Discount	61,102
Increase in inssuance of stock below fair value	1,950,120	1,163,313
Increase in Additional Paid in Capital	5,240	247,723
Increase (Decrease) in Accounts Payable	(76,832)	1,792
(Increase) Decrease in Accounts Receivable
(Increase) Decrease in Notes Receivable
(Increase) Decrease in Interest Receivable	(300)	(300)
Increase (Decrease) in Bank Overdraft
Increase (Decrease) in Accrued Expenses	72,060	25,495
(Increase) Decrease in Prepaid Expenses	8,894	9,000
(Increase) Decrease in Due from Former Employee	0	(15,000)
Net Cash Provided by (Used in) Operating Activities	(504,295)	(425,403)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	267,500	321,667
Preferred Stock issued for Cash	292,500	238,334
Increase in Contributed Capital
Increase (Decrease) in Notes Payable	(74,809)	(54,701)
Increase in Convertible Notes Payable	240,000
Increase (Decrease) in Due to Shareholder	(25,000)	50,000
Net Cash Provided by (Used in) Financing Activities	700,191	555,300
Net Increase (Decrease) in Cash	195,896	129,897
Cash at Beginning of Period	24,822	38,620
Cash at End of Period	220,718	168,517
Supplemental Disclosure of Noncash Investing and Financing Activities:
Common Shares Issued for Debt	0
Preferred Shares Issued for Debt	0
Cash Paid for Interest	$ 1,000

XML 25 R7.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a controlled subsidiary of Bio-Matrix Scientific Group, Inc, (“BMSN”) a Delaware corporation.

A. BASIS OF ACCOUNTING

B. USE OF ESTIMATES

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT

E. FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .

I. REVENUE RECOGNITION

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a controlled subsidiary of Bio-Matrix Scientific Group, Inc, (“BMSN”) a Delaware corporation.

A. BASIS OF ACCOUNTING

B. USE OF ESTIMATES

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. PROPERTY AND EQUIPMENT

E. FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

G. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

H. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .

I. REVENUE RECOGNITION

XML 26 R8.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

3 Months Ended

Dec. 31, 2016

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 27 R9.htm IDEA: XBRL DOCUMENT

Going Concern

3 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 3. GOING CONCERN

XML 28 R10.htm IDEA: XBRL DOCUMENT

Notes Payable

3 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Notes Payable

NOTE 4. NOTES PAYABLE

	December 31, 2016
David Koos ( Note 8)		50
Bostonia Partners		68,588
Notes payable	$	68,638

$50 lent to the Company by David Koos. is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$5,288 lent to the Company by Bostonia Partners is due and payable March 8, 2017 and bears simple interest at a rate of 10% per annum.

$63,300 lent to the Company by Bostonia Partners is due and payable May 10 2017 and bears simple interest at a rate of 10% per annum.

XML 29 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

3 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Convertible Notes Payable

NOTE 5. CONVERTIBLE NOTES PAYABLE

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible notes outstanding is $ 34,625. As of September 30, 2016 $100,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is $25,000.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 8,317. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is $12,500.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 45,205. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 47,123. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 48,630. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

XML 30 R12.htm IDEA: XBRL DOCUMENT

Notes Receivable

3 Months Ended

Dec. 31, 2016

Receivables [Abstract]

Notes Receivable

NOTE 6. NOTES RECEIVABLE

	December 31, 2016
Entest Biomedical, Inc. (Note 8)	$	12,051
Notes Receivable	$	12,051

$12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

XML 31 R13.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 7. INCOME TAXES

As of December 31, 2016

Deferred tax assets:
Net operating tax carry forwards	$	7,	734,625
Other		-0-
Gross deferred tax assets		7,734,625
Valuation allowance		(7,734,625)
Net deferred tax assets	$	-0-

As of December 31, 2016 the Company has a Deferred Tax Asset of $7,734,625completely attributable to net operating loss carry forwards of approximately $22,748,898 (which expire 20 years from the date the loss was incurred).

Income tax is calculated at the 34% Federal Corporate Rate.

XML 32 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Dec. 31, 2016

Related Party Transactions

NOTE 8. RELATED PARTY TRANSACTIONS

The Agreement may be terminated by The Company:

The Agreement may be terminated by either party in the event of a material breach by the other party.

During the quarter ended September 30, 2016 Zander paid $17,000 to the Company as a partial payment of the July 15^th,2016 liability

David R. Koos serves as sole officer and director of both Zander and Entest Biomedical, Inc. and also serves as Chairman and Chief Executive Officer of The Company.

XML 33 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 9. COMMITMENTS AND CONTINGENCIES

XML 34 R16.htm IDEA: XBRL DOCUMENT

Stockholders Equity

3 Months Ended

Dec. 31, 2016

Equity [Abstract]

Stockholders Equity

NOTE 10. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31, 2016:

Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 145,412,605 shares issued and outstanding.

Series AA Preferred Stock

Series A Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 35 R17.htm IDEA: XBRL DOCUMENT

Investment Securities

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Investment Securities

11. INVESTMENT SECURITIES

The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities as of December 31, 2016.

As of December 31, 2016:

	8,000,000		Common Shares of Entest Biomedical, Inc.

	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2016
$	192,000	$	$312,000	120,000	200,000

- Definition

Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.M)
-URI http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

XML 36 R18.htm IDEA: XBRL DOCUMENT

Stock Transactions

3 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Stock Transactions

NOTE 12. STOCK TRANSACTIONS

Common Stock

On November 8, 2016 the Company sold 5,000,000 of its Common Shares for consideration of $112,500.

On November 9, 2016 the Company sold 500,000 of its Common Shares for consideration of $12,500.

On December 19, 2016 the Company sold 7,700,000 of its Common Shares for consideration of $142,500

Series A Preferred Stock

On November 8, 2016 the Company sold 5,000,000 of its Series A Preferred Shares for consideration of $112,500.

n November 9, 2016 the Company sold 500,000 of its Series A Preferred Shares for consideration of $12,5000

On December 19, 2016 the Company sold 9,700,000 of its Series A Preferred Shares for consideration of $ 167,500

Cancellation of Officer Shares

XML 37 R19.htm IDEA: XBRL DOCUMENT

Changes Affecting Comparibility

3 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Changes Affecting Comparibility

NOTE 13. CHANGES AFFECTING COMPARIBILITY

XML 38 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Dec. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

NOTE 14. SUBSEQUENT EVENTS

On January 5, 2017 the Company sold 1,000,000 of its Common Shares for consideration of $12,500

On January 5, 2017 the Company sold 1,000,000 of its Series A Preferred Shares for consideration of $ 12,500

XML 39 R21.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	D. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	E. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
INCOME TAXES	F. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2016 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	G. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	H. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended December 31, 2016 .
REVENUE RECOGNITION	I. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

XML 40 R22.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

3 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Notes Payable

	December 31, 2016
David Koos ( Note 8)		50
Bostonia Partners		68,588
Notes payable	$	68,638

XML 41 R23.htm IDEA: XBRL DOCUMENT

Notes Receivable (Tables)

3 Months Ended

Dec. 31, 2016

Receivables [Abstract]

Notes Receivable

	December 31, 2016
Entest Biomedical, Inc. (Note 8)	$	12,051

Notes Receivable	$	12,051

XML 42 R24.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

3 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Deferred tax assets

Deferred tax assets:
Net operating tax carry forwards	$	7,734,625
Other		-0-
Gross deferred tax assets		7,734,625
Valuation allowance		(7,734,625)
Net deferred tax assets	$	-0-

XML 43 R25.htm IDEA: XBRL DOCUMENT

Investment Securities (Tables)

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Comprehensive Income

11. INVESTMENT SECURITIES

The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities as of December 31, 2016.

As of December 31, 2016:

	8,000,000		Common Shares of Entest Biomedical, Inc.

	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2016
$	192,000	$	$312,000	120,000	200,000

XML 44 R26.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Advertising expenses	$ 0	$ 0
Valuation allowance	100.00%

XML 45 R27.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	3 Months Ended	56 Months Ended
Going Concern (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	$ (2,524,579)	$ (22,748,898)
Issuance of equity securities for cash	1,254,751
Issuance of convertible debt	$ 300,000

XML 46 R28.htm IDEA: XBRL DOCUMENT

Notes Payable and Convertible Notes Payable - Notes Payable (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Notes Payable	$ 68,638	$ 143,447
David Koos
Notes Payable	50
Bostonia Partners
Notes Payable	$ 68,588

XML 47 R29.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
Notes Payable (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
David Koos
Note payable	$ 50
Interest rate per annum		10.00%	10.00%
Bostonia Partners
Note payable	$ 5,288
Interest rate per annum	10.00%
Maturity Date	Mar. 08, 2017
Bostonia Partners 2
Note payable	$ 63,300
Interest rate per annum	10.00%
Maturity Date	May 10, 2017

XML 48 R30.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

5 Months Ended

6 Months Ended

11 Months Ended

12 Months Ended

Oct. 07, 2016

Oct. 31, 2016

Dec. 22, 2016

Mar. 08, 2016

Apr. 06, 2016

Sep. 08, 2016

Aug. 26, 2016

Sep. 20, 2016

Convertible note issued and outstanding

$ 50,000

$ 40,000

$ 100,000

$ 50,000

Convertible note, interest rate

10.00%

8.00%

10.00%

Convertible note, terms

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.01 per share.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 47,123. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 47,123. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 48,630. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2016 the unamortized discount on the convertible note outstanding is $ 48,630. As of September 30, 2016 $50,000 of the principal amount of the Note remains outstanding.

The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2016 is :

(a)

$450,000 if the entire principal amount is converted into common stock

(b)

$430,000 if the entire principal amount is converted into Series A Preferred stock

Beneficial conversion feature

$ 50,000

$ 40,000

$ 42,600

$ 9,900

$ 50,000

Unamortized discount

$ 44,178

$ 39,013

$ 31,085

$ 7,495

$ 34,657

$ 32,739

$ 36,164

Convertible Notes Payable

Convertible note issued and outstanding

$ 50,000

Convertible note, interest rate

10.00%

Convertible note, terms

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

Beneficial conversion feature

$ 50,000

Unamortized discount

45,821

Convertible Notes Payable #2

Convertible note issued and outstanding

$ 50,000

Convertible note, interest rate

10.00%

Convertible note, terms

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

Beneficial conversion feature

$ 50,000

Unamortized discount

45,821

Convertible Notes Payable #3

Convertible note issued and outstanding

$ 50,000

Convertible note, interest rate

10.00%

Convertible note, terms

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

Beneficial conversion feature

$ 50,000

Unamortized discount

$ 45,821

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 49 R31.htm IDEA: XBRL DOCUMENT

Notes Receivable - Notes Receivable (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Notes Receivable	$ 12,051
Entest Biomedical, Inc
Notes Receivable		$ 12,051

XML 50 R32.htm IDEA: XBRL DOCUMENT

Notes Receivable (Details Narrative) - USD ($)	3 Months Ended
Notes Receivable (Details Narrative) - USD ($)	Dec. 31, 2015	Sep. 30, 2016
Notes Receivable		$ 12,051
Entest Biomedical, Inc
Notes Receivable	$ 12,051
Interest rate per annum	10.00%

XML 51 R33.htm IDEA: XBRL DOCUMENT

Income Taxes - Deferred tax assets (Details)	Dec. 31, 2016 USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 7,734,625
Other	0
Gross deferred tax assets	7,734,625
Valuation allowance	(7,734,625)
Net deferred tax assets	$ 0

XML 52 R34.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	3 Months Ended
Income Taxes (Details Narrative)	Dec. 31, 2016 USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 7,734,625
Net operating loss carry forwards	$ 22,748,898
Federal corporate rate	34.00%

XML 53 R35.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended			12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2016
Capital contributions from related party	$ 728,658
Common shares issued to BMSN	50,010,000
Value of shares issued to BMSN	$ 20,090
Monthly rent payable to Entest	5,000
Notes Receivable		$ 12,051		$ 12,051
Notes Payable, Total amount	68,638	143,447		143,447
License fee	$ 100,000	17,000
Royalties receivable, percentage	4.00%
Royalties, receivable		$ 10,000		$ 10,000
Common shares issued in satisfaction of license fee		8,000,000		8,000,000
Revenue recognized equivalent to fair value of common shares	$ 192,000
David Koos
Interest rate per annum			10.00%	10.00%
Notes Payable, Total amount	50
Note payable	$ 50

XML 54 R36.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	3 Months Ended
Commitments and Contingencies (Details Narrative)	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payable to Entest	$ 5,000

XML 55 R37.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Details Narrative) - $ / shares	3 Months Ended
Stockholders Equity (Details Narrative) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Jan. 05, 2017	Dec. 19, 2016	Nov. 09, 2016	Nov. 08, 2016	Sep. 30, 2016
Common stock, Par value	$ 0.0001						$ 0.0001
Common stock, authorized	500,000,000						500,000,000
Common stock issued and outstanding							139,712,605
Preferred stock, par value	$ 0.0001						$ .0001
Preferred stock, authorized	800,000,000						100,000,000
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001						$ 0.0001
Preferred stock, authorized	600,000						600,000
Preferred stock, shares issued and outstanding	30,000						30,000
Preferred stock, shares outstanding	30,000						30,000
Preferred shares voting		With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000).
Series A Preferred Stock
Preferred stock, par value	$ 0.0001						$ 0.0001
Preferred stock, authorized	300,000,000						300,000,000
Preferred stock, shares issued and outstanding	147,966,697		1,000,000				139,712,605
Preferred stock, shares outstanding	147,966,697						139,712,605
Common Stock
Common stock issued and outstanding				7,700,000	500,000	5,000,000
Preferred stock, non-cumulative cash dividends	$ .01
Preferred shares voting	Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

XML 56 R38.htm IDEA: XBRL DOCUMENT

Investment Securities (Details) - USD ($)	3 Months Ended
Investment Securities (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Accounting Policies [Abstract]
Investment Securities, Basis	$ 192,000
Investment Securities, Fair Value	312,000	$ 112,000
Investment Securities, Total Unrealized Losses	120,000
Investment Securities, Net Unrealized Loss during the quarter	$ 200,000

XML 57 R39.htm IDEA: XBRL DOCUMENT

Investment Securities (Details Narrative) - USD ($)	3 Months Ended
Investment Securities (Details Narrative) - USD ($)	Dec. 31, 2016	Sep. 28, 2015
Accounting Policies [Abstract]
Stock issued as license fee, shares		8,000,000
Stock issued as license fee, value		$ 100,000
Common shares of Entest Biomedical, Inc	8,000,000

XML 58 R40.htm IDEA: XBRL DOCUMENT

Stock Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Stock Transactions (Details Narrative) - USD ($)	Nov. 09, 2016	Dec. 31, 2016	Dec. 19, 2016	Jan. 05, 2017	Nov. 08, 2016	Sep. 30, 2016
Common Shares issued						139,712,605
Cash consideration		$ 14,540				$ 13,970
Transaction #2
Preferred stock value	$ 12,500
Transaction #3
Preferred stock issued			9,700,000
Preferred stock value			$ 167,500
Common Stock
Common Shares issued	500,000		7,700,000		5,000,000
Cash consideration	$ 12,500		$ 142,500		$ 112,500
Common Stock \| Todd Caven
Shares Cancelled		7,500,000
Series A Preferred Stock
Preferred stock issued		147,966,697		1,000,000		139,712,605
Series A Preferred Stock \| Todd Caven
Shares Cancelled		2,500,000
Series A Preferred Stock \| Transaction #1
Cash consideration		$ 12,500
Preferred stock value		$ 112,500
Series A Preferred Stock \| Transaction #2
Preferred stock issued	500,000

XML 59 R41.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	Jan. 10, 2017	Jan. 05, 2017	Dec. 31, 2016	Sep. 30, 2016
Common Shares issued				139,712,605
Cash consideration			$ 14,540	$ 13,970
Preferred stock shares authorized			800,000,000	100,000,000
Preferred stock par value			$ 0.0001	$ .0001
Common Stock
Common Shares issued		1,000,000
Cash consideration		$ 12,500
Series M Preferred Stock
Preferred stock shares authorized	300,000,000
Preferred stock par value	$ 0.0001
Series A Preferred Stock
Preferred stock, shares issued		1,000,000	147,966,697	139,712,605
Preferred stock value		$ 12,500
Preferred stock shares authorized			300,000,000	300,000,000
Preferred stock par value			$ 0.0001	$ 0.0001

EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 61 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 58 177 1 false 16 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://regenbiopharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheet (Unaudited) Sheet http://regenbiopharma.com/role/BalanceSheet Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheet (Unaudited) (Parenthetical) Sheet http://regenbiopharma.com/role/BalanceSheetParenthetical Balance Sheet (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statement of Operations (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfOperations Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statement of Comprehensive Income (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfComprehensiveIncome Statement of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statement of Cash Flows (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfCashFlows Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Recent Accounting Pronouncements Sheet http://regenbiopharma.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern Sheet http://regenbiopharma.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Notes Payable Notes http://regenbiopharma.com/role/NotesPayable Notes Payable Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Notes Payable Notes http://regenbiopharma.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Notes Receivable Notes http://regenbiopharma.com/role/NotesReceivable Notes Receivable Notes 12 false false R13.htm 00000013 - Disclosure - Income Taxes Sheet http://regenbiopharma.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - Related Party Transactions Sheet http://regenbiopharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://regenbiopharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders Equity Sheet http://regenbiopharma.com/role/StockholdersEquity Stockholders Equity Notes 16 false false R17.htm 00000017 - Disclosure - Investment Securities Sheet http://regenbiopharma.com/role/InvestmentSecurities Investment Securities Notes 17 false false R18.htm 00000018 - Disclosure - Stock Transactions Sheet http://regenbiopharma.com/role/StockTransactions Stock Transactions Notes 18 false false R19.htm 00000019 - Disclosure - Changes Affecting Comparibility Sheet http://regenbiopharma.com/role/ChangesAffectingComparibility Changes Affecting Comparibility Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://regenbiopharma.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Notes Payable (Tables) Notes http://regenbiopharma.com/role/NotesPayableTables Notes Payable (Tables) Tables http://regenbiopharma.com/role/NotesPayable 22 false false R23.htm 00000023 - Disclosure - Notes Receivable (Tables) Notes http://regenbiopharma.com/role/NotesReceivableTables Notes Receivable (Tables) Tables http://regenbiopharma.com/role/NotesReceivable 23 false false R24.htm 00000024 - Disclosure - Income Taxes (Tables) Sheet http://regenbiopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://regenbiopharma.com/role/IncomeTaxes 24 false false R25.htm 00000025 - Disclosure - Investment Securities (Tables) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesTables Investment Securities (Tables) Tables http://regenbiopharma.com/role/InvestmentSecurities 25 false false R26.htm 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 00000027 - Disclosure - Going Concern (Details Narrative) Sheet http://regenbiopharma.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://regenbiopharma.com/role/GoingConcern 27 false false R28.htm 00000028 - Disclosure - Notes Payable and Convertible Notes Payable - Notes Payable (Details) Notes http://regenbiopharma.com/role/NotesPayableAndConvertibleNotesPayable-NotesPayableDetails Notes Payable and Convertible Notes Payable - Notes Payable (Details) Details 28 false false R29.htm 00000029 - Disclosure - Notes Payable (Details Narrative) Notes http://regenbiopharma.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://regenbiopharma.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://regenbiopharma.com/role/ConvertibleNotesPayable 30 false false R31.htm 00000031 - Disclosure - Notes Receivable - Notes Receivable (Details) Notes http://regenbiopharma.com/role/NotesReceivable-NotesReceivableDetails Notes Receivable - Notes Receivable (Details) Details 31 false false R32.htm 00000032 - Disclosure - Notes Receivable (Details Narrative) Notes http://regenbiopharma.com/role/NotesReceivableDetailsNarrative Notes Receivable (Details Narrative) Details http://regenbiopharma.com/role/NotesReceivableTables 32 false false R33.htm 00000033 - Disclosure - Income Taxes - Deferred tax assets (Details) Sheet http://regenbiopharma.com/role/IncomeTaxes-DeferredTaxAssetsDetails Income Taxes - Deferred tax assets (Details) Details 33 false false R34.htm 00000034 - Disclosure - Income Taxes (Details Narrative) Sheet http://regenbiopharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://regenbiopharma.com/role/IncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://regenbiopharma.com/role/RelatedPartyTransactions 35 false false R36.htm 00000036 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://regenbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://regenbiopharma.com/role/CommitmentsAndContingencies 36 false false R37.htm 00000037 - Disclosure - Stockholders Equity (Details Narrative) Sheet http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative Stockholders Equity (Details Narrative) Details http://regenbiopharma.com/role/StockholdersEquity 37 false false R38.htm 00000038 - Disclosure - Investment Securities (Details) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesDetails Investment Securities (Details) Details http://regenbiopharma.com/role/InvestmentSecuritiesTables 38 false false R39.htm 00000039 - Disclosure - Investment Securities (Details Narrative) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative Investment Securities (Details Narrative) Details http://regenbiopharma.com/role/InvestmentSecuritiesTables 39 false false R40.htm 00000040 - Disclosure - Stock Transactions (Details Narrative) Sheet http://regenbiopharma.com/role/StockTransactionsDetailsNarrative Stock Transactions (Details Narrative) Details http://regenbiopharma.com/role/StockTransactions 40 false false R41.htm 00000041 - Disclosure - Subsequent Events (Details Narrative) Sheet http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://regenbiopharma.com/role/SubsequentEvents 41 false false All Reports Book All Reports rgbp-20161231.xml rgbp-20161231.xsd rgbp-20161231_cal.xml rgbp-20161231_def.xml rgbp-20161231_lab.xml rgbp-20161231_pre.xml true true ZIP 66 0001607062-17-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-17-000038-xbrl.zip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end